248 related articles for article (PubMed ID: 10741860)
21. HLA-DM can partially replace the invariant chain for HLA-DR transport and surface expression in transfected endocrine epithelial cells.
Serradell L; Muntasell A; Catálfamo M; Martí M; Costa M; de Préval C; Jaraquemada D
Tissue Antigens; 1999 May; 53(5):447-58. PubMed ID: 10372540
[TBL] [Abstract][Full Text] [Related]
22. Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs.
van Ham SM; Grüneberg U; Malcherek G; Bröker I; Melms A; Trowsdale J
J Exp Med; 1996 Nov; 184(5):2019-24. PubMed ID: 8920889
[TBL] [Abstract][Full Text] [Related]
23. Herpes simplex virus type 1 targets the MHC class II processing pathway for immune evasion.
Neumann J; Eis-Hübinger AM; Koch N
J Immunol; 2003 Sep; 171(6):3075-83. PubMed ID: 12960333
[TBL] [Abstract][Full Text] [Related]
24. Extracellular antigen processing and presentation by immature dendritic cells.
Santambrogio L; Sato AK; Carven GJ; Belyanskaya SL; Strominger JL; Stern LJ
Proc Natl Acad Sci U S A; 1999 Dec; 96(26):15056-61. PubMed ID: 10611337
[TBL] [Abstract][Full Text] [Related]
25. Modulation of the major histocompatibility complex class II-associated peptide repertoire by human histocompatibility leukocyte antigen (HLA)-DO.
van Ham M; van Lith M; Lillemeier B; Tjin E; Grüneberg U; Rahman D; Pastoors L; van Meijgaarden K; Roucard C; Trowsdale J; Ottenhoff T; Pappin D; Neefjes J
J Exp Med; 2000 Apr; 191(7):1127-36. PubMed ID: 10748231
[TBL] [Abstract][Full Text] [Related]
26. Type 1 diabetes associated HLA-DQ2 and DQ8 molecules are relatively resistant to HLA-DM mediated release of invariant chain-derived CLIP peptides.
Zhou Z; Reyes-Vargas E; Escobar H; Rudd B; Rockwood AL; Delgado JC; He X; Jensen PE
Eur J Immunol; 2016 Apr; 46(4):834-45. PubMed ID: 26707565
[TBL] [Abstract][Full Text] [Related]
27. Mechanistic understanding and significance of small peptides interaction with MHC class II molecules for therapeutic applications.
Afridi S; Hoessli DC; Hameed MW
Immunol Rev; 2016 Jul; 272(1):151-68. PubMed ID: 27319349
[TBL] [Abstract][Full Text] [Related]
28. Peptidomic analysis of type 1 diabetes associated HLA-DQ molecules and the impact of HLA-DM on peptide repertoire editing.
Zhou Z; Reyes-Vargas E; Escobar H; Chang KY; Barker AP; Rockwood AL; Delgado JC; He X; Jensen PE
Eur J Immunol; 2017 Feb; 47(2):314-326. PubMed ID: 27861808
[TBL] [Abstract][Full Text] [Related]
29. Differential up-regulation of HLA-DM, invariant chain, and CD83 on myeloid and plasmacytoid dendritic cells from peripheral blood.
Gómez J; Borràs FE; Singh R; Rajananthanan P; English N; Knight SC; Navarrete CV
Tissue Antigens; 2004 Feb; 63(2):149-57. PubMed ID: 14705986
[TBL] [Abstract][Full Text] [Related]
30. Impaired antigen presentation by murine I-Ad class II MHC molecules expressed in normal and HLA-DM-defective human B cell lines.
Weenink S; Averdunk H; Boston T; Boswarva V; Guery JC; Adorini L; Mellins E; McCluskey J; Gautam AM
Int Immunol; 1997 Jun; 9(6):889-96. PubMed ID: 9199972
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms underlying the lack of endogenous processing and CLIP-mediated binding of the invariant chain by HLA-DP
Anczurowski M; Yamashita Y; Nakatsugawa M; Ochi T; Kagoya Y; Guo T; Wang CH; Rahman MA; Saso K; Butler MO; Hirano N
Sci Rep; 2018 Mar; 8(1):4804. PubMed ID: 29555965
[TBL] [Abstract][Full Text] [Related]
32. Dissection of the HLA-DR4 peptide repertoire in endocrine epithelial cells: strong influence of invariant chain and HLA-DM expression on the nature of ligands.
Muntasell A; Carrascal M; Alvarez I; Serradell L; van Veelen P; Verreck FA; Koning F; Abian J; Jaraquemada D
J Immunol; 2004 Jul; 173(2):1085-93. PubMed ID: 15240697
[TBL] [Abstract][Full Text] [Related]
33. HLA-DM, HLA-DO and tapasin: functional similarities and differences.
Brocke P; Garbi N; Momburg F; Hämmerling GJ
Curr Opin Immunol; 2002 Feb; 14(1):22-9. PubMed ID: 11790529
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms of peptide repertoire selection by HLA-DM.
Pos W; Sethi DK; Wucherpfennig KW
Trends Immunol; 2013 Oct; 34(10):495-501. PubMed ID: 23835076
[TBL] [Abstract][Full Text] [Related]
35. DM influences the abundance of major histocompatibility complex class II alleles with low affinity for class II-associated invariant chain peptides via multiple mechanisms.
Rinderknecht CH; Roh S; Pashine A; Belmares MP; Patil NS; Lu N; Truong P; Hou T; Macaubas C; Yoon T; Wang N; Busch R; Mellins ED
Immunology; 2010 Sep; 131(1):18-32. PubMed ID: 20408893
[TBL] [Abstract][Full Text] [Related]
36. How HLA-DM affects the peptide repertoire bound to HLA-DR molecules.
Vogt AB; Kropshofer H; Hämmerling GJ
Hum Immunol; 1997 May; 54(2):170-9. PubMed ID: 9297535
[TBL] [Abstract][Full Text] [Related]
37. HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers and facilitates peptide loading.
Denzin LK; Cresswell P
Cell; 1995 Jul; 82(1):155-65. PubMed ID: 7606781
[TBL] [Abstract][Full Text] [Related]
38. Functional HLA-DM on the surface of B cells and immature dendritic cells.
Arndt SO; Vogt AB; Markovic-Plese S; Martin R; Moldenhauer G; Wölpl A; Sun Y; Schadendorf D; Hämmerling GJ; Kropshofer H
EMBO J; 2000 Mar; 19(6):1241-51. PubMed ID: 10716924
[TBL] [Abstract][Full Text] [Related]
39. Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentation.
Carstens C; Newman DK; Bohlen H; König A; Koch N
Int Immunol; 2000 Nov; 12(11):1561-8. PubMed ID: 11058576
[TBL] [Abstract][Full Text] [Related]
40. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
